Randomized Trial for Non-small Cell Lung Cancer after Progression on EGFR TKI

Trial ID:
Michael P. Kosty, M.D.
This study will compare the safety and effectiveness of patritumab deruxtecan to standard of care platinum-based chemotherapy. Patients will be randomized (like the flip of a coin) to receive either patritumab deruxtecan or platinum-based chemotherapy and will know which treatment they are receiving. Patritumab deruxtecan is an investigational drug being used only in research.

Inclusion Criteria

Patients must:
  • Have EGFR-mutated Non-small Cell Lung Cancer.
  • Have disease progression while receiving a third-generation EGFR TKI (such as Tagrisso).
  • Be ambulatory and able to carry out work of a light or sedentary nature. For example, must be capable of performing light housework or office work.
  • Be willing to provide tumor tissue by either a new tumor biopsy or from a previous biopsy performed on or after treatment with EGFR TKI.

Exclusion Criteria

Patients must not:
  • Have received other prior systemic cancer therapies (including chemotherapy, immunotherapy, etc) since being diagnosed with metastatic or locally advanced disease.
  • Have clinically active brain metastases or spinal cord compression.
  • Have a history of interstitial lung disease, severe respiratory compromise, or significant cardiovascular disease.
  • Be pregnant or nursing.

Additional Info

  • All physician visits and study treatments will occur at Scripps Clinic Torrey Pines (Geisel Pavilion) and Scripps MD Anderson Prebys Cancer Center.
  • Participation in the study will last for up to 49 months.
  • Search for NCT05338970 on https://clinicaltrials.gov/ for additional information.

Contact Info:

  • Clinical Research Services
  • CRSLeadership@scrippshealth.org